Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist (2026)
https://pubmed.ncbi.nlm.nih.gov/42689760/

Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis (2026)
https://pubmed.ncbi.nlm.nih.gov/42386286/

Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data (2026)
https://pubmed.ncbi.nlm.nih.gov/41820781/

Sustained improvements in health status and work productivity with bimekizumab in psoriatic arthritis: 2-year results from two phase 3 studies (2026)
https://pubmed.ncbi.nlm.nih.gov/41710044/

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors (2026)
https://pubmed.ncbi.nlm.nih.gov/41269519/

Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors (2026)
https://pubmed.ncbi.nlm.nih.gov/41208804/

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors (2026)
https://pubmed.ncbi.nlm.nih.gov/41239039/

Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe (2025)
https://pubmed.ncbi.nlm.nih.gov/41128765/

World Café Report From the GRAPPA 2024 Annual Meeting and Trainee Symposium: Exploring GRAPPA’s Future Priorities (2025)
https://pubmed.ncbi.nlm.nih.gov/40953949/

Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations (2025)
https://pubmed.ncbi.nlm.nih.gov/40854555/

Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns (2025)
https://pubmed.ncbi.nlm.nih.gov/40704853/

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort (2025)
https://pubmed.ncbi.nlm.nih.gov/40123255/

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial (2025)
https://pubmed.ncbi.nlm.nih.gov/40102973/

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium (2025)
https://pubmed.ncbi.nlm.nih.gov/39919898/

Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial (2025)
https://pubmed.ncbi.nlm.nih.gov/39671076/

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors (2025)
https://pubmed.ncbi.nlm.nih.gov/39621228/

Autoimmune Disease is Increased in Women With Primary Ovarian Insufficiency (2025)
https://pubmed.ncbi.nlm.nih.gov/39607709/

Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies (2025)
https://pubmed.ncbi.nlm.nih.gov/39406403/

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment (2025)
https://pubmed.ncbi.nlm.nih.gov/39133200/

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies (2024)
https://pubmed.ncbi.nlm.nih.gov/39534481/

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation (2024)
https://pubmed.ncbi.nlm.nih.gov/39133438/

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors (2024)
https://pubmed.ncbi.nlm.nih.gov/39083163/

Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria (2024)
https://pubmed.ncbi.nlm.nih.gov/38858318/

Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis (2024)
https://pubmed.ncbi.nlm.nih.gov/38714073/

Measuring Psoriasis Severity at Home (2024)
https://pubmed.ncbi.nlm.nih.gov/38497631/

Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease (2024)
https://pubmed.ncbi.nlm.nih.gov/38101918/

PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries (2024)
https://pubmed.ncbi.nlm.nih.gov/37691268/

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis (2023)
https://pubmed.ncbi.nlm.nih.gov/37568031/

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 (2023)
https://pubmed.ncbi.nlm.nih.gov/37191738/

The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease (2023)
https://pubmed.ncbi.nlm.nih.gov/37095710/

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies (2023)
https://pubmed.ncbi.nlm.nih.gov/37038159/

Responsiveness and Minimum Clinically Important Difference in Patient-Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study (2023)
https://pubmed.ncbi.nlm.nih.gov/36913210/

Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe (2023)
https://pubmed.ncbi.nlm.nih.gov/36706947/

Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States (2023)
https://pubmed.ncbi.nlm.nih.gov/36318701/

Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Biomarkers in Axial Spondyloarthritis: Observational Studies From the Program to Understand the Longterm Outcomes in Spondyloarthritis Registry (2023)
https://pubmed.ncbi.nlm.nih.gov/36053919/

Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe (2023)
https://pubmed.ncbi.nlm.nih.gov/35970531/

Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/34758105/

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST (2022)
https://pubmed.ncbi.nlm.nih.gov/35853675/

Effect of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey (2022)
https://pubmed.ncbi.nlm.nih.gov/35840154/

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials (2022)
https://pubmed.ncbi.nlm.nih.gov/35429281/

Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/35279798/

Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry (2022)
https://pubmed.ncbi.nlm.nih.gov/35191010/

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial (2022)
https://pubmed.ncbi.nlm.nih.gov/33044756/

Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication (2021)
https://pubmed.ncbi.nlm.nih.gov/34958453/

Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research (2021)
https://pubmed.ncbi.nlm.nih.gov/33259327/

Clinical Manifestations and Diagnosis of Axial Spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33105312/

Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/34724089/

A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health (2021)
https://pubmed.ncbi.nlm.nih.gov/33313838/

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33655380/

Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study (2021)
https://pubmed.ncbi.nlm.nih.gov/33759081/

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry (2021)
https://pubmed.ncbi.nlm.nih.gov/34822121/

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020 (2021)
https://pubmed.ncbi.nlm.nih.gov/34287723/

Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies (2021)
https://pubmed.ncbi.nlm.nih.gov/32669450/

Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods (2020)
https://pubmed.ncbi.nlm.nih.gov/30877217/

Recognizing Axial Spondyloarthritis: A Guide for Primary Care (2020)
https://pubmed.ncbi.nlm.nih.gov/32736944/

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies (2020)
https://pubmed.ncbi.nlm.nih.gov/32271088/

Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease (2020)
https://pubmed.ncbi.nlm.nih.gov/31575704/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2020)
https://pubmed.ncbi.nlm.nih.gov/31685553/

Application of machine learning in the diagnosis of axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31033569/

Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016 (2019)
https://pubmed.ncbi.nlm.nih.gov/31559383/

Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood (2019)
https://pubmed.ncbi.nlm.nih.gov/31128893/

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31254223/

Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis (2019)
https://pubmed.ncbi.nlm.nih.gov/31663467/

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/30499246/

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap (2019)
https://pubmed.ncbi.nlm.nih.gov/31673975/

Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set (2018)
https://pubmed.ncbi.nlm.nih.gov/29637483/

Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set (2018)
https://pubmed.ncbi.nlm.nih.gov/29861786/

Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database (2018)
https://pubmed.ncbi.nlm.nih.gov/29148281/

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA (2018)
https://pubmed.ncbi.nlm.nih.gov/30324088/

Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database (2018)
https://pubmed.ncbi.nlm.nih.gov/29557701/

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial (2018)
https://pubmed.ncbi.nlm.nih.gov/30191421/

PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol (2018)
https://pubmed.ncbi.nlm.nih.gov/29717036/

Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance (2018)
https://pubmed.ncbi.nlm.nih.gov/29142040/

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) (2018)
https://pubmed.ncbi.nlm.nih.gov/29343507/